On this new season of Prognosis, we look at the spread of infections that are resistant to antimicrobial medicines. You're probably more likely to have heard of these as superbugs. Their rise has been described as a silent tsunami of catastrophic proportions. We travel to countries on the frontline of the crisis, and explore how hospitals and doctors around the world are fighting back. Prognosis’ new season launches Sept. 5. 

On this new season of Prognosis, we look at the spread of infections that are resistant to antimicrobial medicines. You're probably more likely to have heard of these as superbugs. Their rise has been described as a silent tsunami of catastrophic proportions. We travel to countries on the frontline of the crisis, and explore how hospitals and doctors around the world are fighting back. Prognosis’ new season launches Sept. 5.

Money goes where it’s treated best. That simple truth is a big reason why more and more money (trillions, in fact) flows into a powerful, low-cost tool that’s quietly transformed investing. Exchange-traded funds let you invest in everything from the stock market to gold like never before. This biweekly podcast will demystify them—and hopefully delight you in the process.

Money goes where it&rsquo;s treated best. That simple truth is a big reason why more and more money (trillions, in fact) flows into a powerful, low-cost tool that&rsquo;s quietly transformed investing. Exchange-traded funds let you invest in everything from the stock market to gold like never before. This biweekly podcast will demystify them&mdash;and hopefully delight you in the process.

Joel Weber and Eric Balchunas demystify the world of exchange-traded funds, or ETFs.

Trillions

Introducing Prognosis Season 3: Superbugs

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/9f1523f7-05f4-4123-b703-ae3c002e0aca/transcript

A long-dormant trade is suddenly showing signs of life. Prices are climbing. Volumes are spiking. And in a corner of the market that’s spent years in the doldrums, one ETF is catching a fresh buzz — thanks in part to the US Justice Department’s move in April to reclassify medical marijuana as a less dangerous drug.

On this episode of Trillions, Eric Balchunas and Joel Weber debut a new monthly segment spotlighting an ETF that’s having a moment. This time, Bloomberg Intelligence’s Andre Yapp joins to break down the AdvisorShares Pure US Cannabis ETF (MSOS). The only cannabis-focused ETF with more than $1 billion in assets, it uses swaps to access marijuana companies just as shifting tax rules begin to ease the industry’s burden. The setup looks promising—but is this a real turning point, or just another short-lived high?

A long-dormant trade is suddenly showing signs of life. Prices are climbing. Volumes are spiking. And in a corner of the market that&rsquo;s spent years in the doldrums, one ETF is catching a fresh buzz &mdash; thanks in part to the US Justice Department&rsquo;s move in April to reclassify medical marijuana as a less dangerous drug.
On this episode of Trillions, Eric Balchunas and Joel Weber debut a new monthly segment spotlighting an ETF that&rsquo;s having a moment. This time, Bloomberg Intelligence&rsquo;s Andre Yapp joins to break down the AdvisorShares Pure US Cannabis ETF (MSOS). The only cannabis-focused ETF with more than $1 billion in assets, it uses swaps to access marijuana companies just as shifting tax rules begin to ease the industry&rsquo;s burden. The setup looks promising&mdash;but is this a real turning point, or just another short-lived high?

ETF of the Moment: A Budding Comeback for Cannabis

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/315bff9d-ecfd-489a-a7cd-b4490147b486/transcript

Markets hate uncertainty — unless, it turns out, they don’t. Under US President Donald Trump, investors have endured tariff scares, geopolitical flare-ups and a steady drumbeat of headline-driven panic. Yet stocks keep climbing; April, in particular, was a blockbuster. Maybe the best way to understand this market is to stop trying to make sense of it.

On this episode of Trillions, Eric Balchunas and Joel Weber speak with Bloomberg Intelligence’s Athanasios Psarofagis about what ETF data actually says about investing during a Trump presidency. His grab bag of stats — March is cursed, Thursdays are rough and some of the biggest gains happen while you sleep — paints a picture of a market behaving very differently under pressure. Together, they unpack why it feels more volatile than ever and explore why the investors who come out ahead are often the ones who do the least.

Markets hate uncertainty &mdash; unless, it turns out, they don&rsquo;t. Under US President Donald Trump, investors have endured tariff scares, geopolitical flare-ups and a steady drumbeat of headline-driven panic. Yet stocks keep climbing; April, in particular, was a blockbuster. Maybe the best way to understand this market is to stop trying to make sense of it.
On this episode of Trillions, Eric Balchunas and Joel Weber speak with Bloomberg Intelligence&rsquo;s Athanasios Psarofagis about what ETF data actually says about investing during a Trump presidency. His grab bag of stats &mdash; March is cursed, Thursdays are rough and some of the biggest gains happen while you sleep &mdash; paints a picture of a market behaving very differently under pressure. Together, they unpack why it feels more volatile than ever and explore why the investors who come out ahead are often the ones who do the least.

 How to Invest During a Trump Presidency

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/6957e592-9578-4706-ac77-b4420138e5d5/transcript

Every day, a handful of new exchange-traded funds come to market. Some rocket to instant glory. Others take their time, building assets month after month, year after year. And more than a few quietly disappear into oblivion.

On this episode of Trillions, Eric Balchunas and Joel Weber debut a new monthly segment that sifts through the flood of launches to pick out three ETFs worth watching. Whether the funds are potential hits, future mainstays or squarely in the “good luck with that” camp, the goal is to figure out what distinguishes them — and how they might help (or hurt) investors. Isabelle Lee, a cross-asset reporter for Bloomberg News, joins to discuss a late Bitcoin arrival, a rare launch and an expensive swing at value investing.

Every day, a handful of new exchange-traded funds come to market. Some rocket to instant glory. Others take their time, building assets month after month, year after year. And more than a few quietly disappear into oblivion. On this episode of Trillions, Eric Balchunas and Joel Weber debut a new monthly segment that sifts through the flood of launches to pick out three ETFs worth watching. Whether the funds are potential hits, future mainstays or squarely in the &ldquo;good luck with that&rdquo; camp, the goal is to figure out what distinguishes them &mdash; and how they might help (or hurt) investors. Isabelle Lee, a cross-asset reporter for Bloomberg News, joins to discuss a late Bitcoin arrival, a rare launch and an expensive swing at value investing.

ETFs to Watch From Morgan Stanley, Vanguard and ... Pzena?

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/be64986c-56fd-4d68-8819-b43b00e82d48/transcript

Introducing Prognosis Season 3: Superbugs

In 1 playlist(s)

Trillions

Social links

Follow podcast

Recent clips